Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Early versus deferred hormonal treatment for symptomatic prostate cancer
Autore:
Mickisch, GHJ;
Indirizzi:
Erasmus Univ, Dept Urol, NL-3015 GD Rotterdam, Netherlands Erasmus Univ Rotterdam Netherlands NL-3015 GD GD Rotterdam, Netherlands Acad Hosp Rotterdam, NL-3015 GD Rotterdam, Netherlands Acad Hosp Rotterdam Rotterdam Netherlands NL-3015 GD terdam, Netherlands
Titolo Testata:
ONKOLOGIE
fascicolo: 3, volume: 24, anno: 2001,
pagine: 214 - 220
SICI:
0378-584X(200106)24:3<214:EVDHTF>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADICAL PROSTATECTOMY; FOLLOW-UP; THERAPY; MANAGEMENT; IMMEDIATE; SURVIVAL; PSA; FINASTERIDE; MULTICENTER; PROGRESSION;
Keywords:
asymptomatic prostate cancer; early treatment; deferred treatment;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Mickisch, GHJ Erasmus Univ, Dept Urol, Room H1073,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands Erasmus Univ Room H1073,Dr Molewaterpl 40 Rotterdam Netherlands NL-3015 GD
Citazione:
G.H.J. Mickisch, "Early versus deferred hormonal treatment for symptomatic prostate cancer", ONKOLOGIE, 24(3), 2001, pp. 214-220

Abstract

There are two different clinical scenarios in which a decision on hormonaltherapy either initially after diagnosis of deferred until the occurrence of signs and symptoms for presently asymptomatic prostate cancer is needed:A more recently described cohort of men with prostate cancer who underwentdefinitive therapy for putatively curable disease experiencing a rising PSA (biochemical relapse/progression), and a more classical group of men withprostate cancer who were unwilling or unfit to undergo local therapy with curative intent. Long-term hormonal treatment will expose patients to the risk of substantial adverse side effects such as muscle wasting, chronic fatigue, osteoporosis and others, in addition to an overall increase in treatment costs. On the other hand, a potential prolongation of survival and a delay in the development of clinical symptoms may serve as arguments for early treatment. A number of studies have been conducted in which early hormonal treatment delays the time to progression and reduces the cancer-related complication rate such as urinary obstruction and bone fractures. However, results on overall survival remain inconclusive and quality-of-life issues will become more and more important in light of the extended life span of patients with asymptomatic prostate cancer in recent years. Ongoing clinical trials such as EORTC 30991 are needed to provide further information on this important issue.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 17:38:12